Adefovir dipivoxil/lamivudine

Drug Profile

Adefovir dipivoxil/lamivudine

Alternative Names: Lamivudine/adefovir dipivoxil

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Class Antiretrovirals; Deoxyribonucleosides; Phosphonic acids; Purine nucleotides; Pyrimidine nucleosides; Small molecules
  • Mechanism of Action DNA-directed DNA polymerase inhibitors; Hepatitis B virus replication inhibitors; Immunomodulators; Nucleotide reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Hepatitis B

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Hepatitis-B(In volunteers) in Hong Kong (PO, Capsule)
  • 30 Apr 2011 GlaxoSmithKline completes a phase I trial in Chronic Hepatitis B in Hong Kong (NCT01353742)
  • 28 Feb 2011 Phase-I clinical trials in Hepatitis B in Hong Kong (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top